223 related articles for article (PubMed ID: 35099022)
1. Comparative evaluation of Sensititre YeastOne and VITEK 2 against the Clinical and Laboratory Standards Institute M27-E4 reference broth microdilution method for the antifungal susceptibility testing of Cryptococcus neoformans and Cryptococcus gattii.
Zhang M; Zhou Z; Wang D; Zhou A; Song G; Chen X; Guo J; Wu W
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35099022
[TBL] [Abstract][Full Text] [Related]
2. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
3. Comparison of MIC Test Strip and Sensititre YeastOne with the CLSI and EUCAST Broth Microdilution Reference Methods for
Delma FZ; Al-Hatmi AMS; Buil JB; van der Lee H; Tehupeiory-Kooreman M; de Hoog GS; Meletiadis J; Verweij PE
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015025
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of the Vitek 2 antifungal susceptibility system and E-test with the CLSI M27-A3 broth microdilution method for susceptibility testing of Indian clinical isolates of Cryptococcus neoformans.
Tewari A; Behera B; Mathur P; Xess I
Mycopathologia; 2012 Jun; 173(5-6):427-33. PubMed ID: 22354778
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India.
Chowdhary A; Randhawa HS; Sundar G; Kathuria S; Prakash A; Khan Z; Sun S; Xu J
J Med Microbiol; 2011 Jul; 60(Pt 7):961-967. PubMed ID: 21393452
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility testing with YeastONE™ is not predictive of clinical outcomes of Cryptococcus neoformans var. grubii fungemia.
Yang JH; Huang PY; Cheng CW; Shie SS; Lin ZF; Yang LY; Lee CH; Wu TS
Med Mycol; 2021 Nov; 59(11):1114-1121. PubMed ID: 34374784
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Etests and Vitek 2 ® to broth microdilution for the susceptibility testing of Cryptococcus neoformans.
Mahabeer Y; Chang CC; Naidu D; Dorasamy A; Lewin S; Ndung'u T; Moosa MY; French M; Mlisana K; Coovadia Y
Diagn Microbiol Infect Dis; 2014 Dec; 80(4):294-8. PubMed ID: 25277745
[TBL] [Abstract][Full Text] [Related]
8. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry.
Morales BP; Junior IN; Trilles L; Bertho AL; Oliveira Rde V; Nishikawa MM; Elias Mdos S; Wanke B; Lazéra Mdos S
Med Mycol; 2014 Jan; 52(1):90-8. PubMed ID: 23808405
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
[TBL] [Abstract][Full Text] [Related]
10. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
11.
Al-Odaini N; Li XY; Li BK; Chen XC; Huang CY; Lv CY; Pan KS; Zheng DY; Zheng YQ; Liao WQ; Cao CW
Front Microbiol; 2021; 12():708280. PubMed ID: 34447360
[TBL] [Abstract][Full Text] [Related]
12. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
13. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms.
Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA
J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817
[TBL] [Abstract][Full Text] [Related]
14. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the VITEK 2 system to test the susceptibility of Candida spp., Trichosporon asahii and Cryptococcus neoformans to amphotericin B, flucytosine, fluconazole and voriconazole: a comparison with the M27-A3 reference method.
Cejudo MA; Gallego AG; Lacasa EC; Aller AI; Romero A; García JP; Andrés GQ; Martín-Mazuelos E
Med Mycol; 2010 Aug; 48(5):710-9. PubMed ID: 20109092
[TBL] [Abstract][Full Text] [Related]
17. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Vitek identification and antifungal susceptibility testing methods to DNA sequencing and Sensititre YeastOne antifungal testing.
Vijgen S; Nys S; Naesens R; Magerman K; Boel A; Cartuyvels R
Med Mycol; 2011 Jan; 49(1):107-10. PubMed ID: 20560861
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Sensititre YeastOne antifungal method with the CLSI M27-A3 reference method to determine the activity of antifungal agents against clinical isolates of Candidaspp.
Altinbaş R; Barış A; Şen S; Öztürk R; Kiraz N
Turk J Med Sci; 2020 Dec; 50(8):2024-2031. PubMed ID: 32659879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
